米托坦（Lysodren）引起的口腔和外阴阴道苔藓样反应：一例报告。
Oral and vulvo-vaginal lichenoid reactions due to mitotane (Lysodren): A case report.
作者信息
Schmouchkovitch Arthur, Herry Héloïse, Thuillier Philippe, Kerlan Véronique, Fleuret Camille, Le Toux Guy, Boisramé Sylvie
机构信息
aDepartment of Dental Surgery bDepartment of Endocrinology, Brest University Hospital, Brest cDepartment of Dermatology, Quimper Hospital, Quimper dDepartment of Oral Surgery, Brest University Hospital, Brest, France.
出版信息
Medicine (Baltimore). 2017 Jan;96(2):e5075. doi: 10.1097/MD.0000000000005075.
BACKGROUND
The purpose of pharmacovigilance (drug safety) is collection, detection, assessment, monitoring, and prevention of adverse effects with pharmaceutical products. It is meant to identify, characterize, prevent, or minimize actual or potential risks relating to medicinal products. To prevent these adverse effects and improve our practice, health professionals have a duty to report side effects to assess this risk and evaluate the benefit/risk requirements. Mitotane (Lysodren) is used for treating adrenocortical carcinoma. Currently, no side effects concerning oral and genital mucosa have been reported.
CASE SUMMARY
This case report is about a 50 years old woman. Six months after the initiation on mitotane treatment, she developed erosive lesions located on the oral and vaginal mucosa. These drug reactions were diagnosed as erosive lichen planus by the biopsy. This lichenoid lesions were resistant to the usual treatments, mitotane being at the time not replaceable.
CONCLUSION
This case describes an unreported adverse effect of mitotane, it is - to our knowledge - the 1st description of erosive lichenoid drug reaction due to Mitotane.
背景
药物警戒（药品安全）的目的是收集、发现、评估、监测和预防药品的不良反应。其旨在识别、表征、预防或最小化与药品相关的实际或潜在风险。为预防这些不良反应并改进我们的做法，卫生专业人员有责任报告副作用以评估此风险并评估效益/风险要求。米托坦（氯苯二氯乙烷）用于治疗肾上腺皮质癌。目前，尚未有关于口腔和生殖器黏膜副作用的报告。
病例摘要
本病例报告是关于一名50岁女性。在开始米托坦治疗6个月后，她出现了位于口腔和阴道黏膜的糜烂性病变。经活检，这些药物反应被诊断为糜烂性扁平苔藓。这些苔藓样病变对常规治疗有抵抗性，当时米托坦不可替代。
结论
本病例描述了米托坦一种未报告的不良反应，据我们所知，这是首例因米托坦引起的糜烂性苔藓样药物反应的描述。
Zotero 插件